Is UHS a good stock to buy?
Universal Health Services, Inc. · end-of-day data as of Nov 13, 2026
- P/E vs sector-74.8%
- FCF yield+11.4%
- MAs4 of 4
- MACD0.86
- Sector▲ +15.9%
- Earnings in103d
- P/E8.1x
- RSI59
- Support-3.2%
- Resistance+1.3%
- Off 52w high-21.2%
- Volume0.6x
- Bollingerupper half
- News0.00
- P/E vs own+7.0%
- ConsensusHold · 21
- Trendsideways
- 52w range$140–$246
- ATR+3.5%
- Off ATH-21.2%
- InsidersNone in 90d
- PT$193.22 -0.4%
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Universal Health Services a good stock to buy?
Universal Health Services is strong on 3 of the 5 questions about the business. The price is low: 8.1 times its earnings, below its 3-year median of 10.2 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand growing
- Advantage some edge
- Economics profitable
- Execution delivers
- Fragility sturdy
- Price below its usual
UHS sales growth revenue growth
+9%a year, for the last 3 yearsUniversal Health Services' sales grew 9% a year for 3 years, to $17.36B in fiscal 2025.
UHS analysts' forecast revenue estimates
+7%the sales they expect next fiscal year, on the lastAnalysts expect Universal Health Services' sales to grow 7% to $18.61B in fiscal 2026 (15 analysts).
UHS peers
pretickt analysis+8%its sales in 12 months, on a year before
Universal Health Services' sales grew 8% in the 12 months to Sep 30, 2026, faster than DaVita (+6%), Henry Schein (+6%) and HCA Healthcare (+6%), slower than Insulet (+26%).
UHS sales by business revenue by segment
57%of its sales from Acute Care Hospital ServicesAcute Care Hospital Services brought Universal Health Services 57% of its sales in fiscal 2025; Behavioral Health Services 43%.
UHS return on capital ROIC
pretickt analysis15%earned before tax on the money invested in itUniversal Health Services earned 15% before tax on the capital invested in it in the 12 months to Sep 30, 2026; Insulet 30%, HCA Healthcare 28%, DaVita 17% and Henry Schein 11%.
UHS margin on each sale gross margin
70%left after making the productUniversal Health Services kept 70% of each sale after making the product in the 12 months to Sep 30, 2026; its peers' median is 31%.
UHS margin after costs profit margin
11%of sales left after running the businessUniversal Health Services' operating margin was 11% in the 12 months to Sep 30, 2026, against 7% in fiscal 2022.
UHS cash generated free cash flow
$1.12Bcash left after investing, last 12 monthsUniversal Health Services generated $1.12B of free cash flow in the 12 months to Sep 30, 2026, less than its reported profit.
UHS earnings vs estimates
7 of 8quarters above the analysts' estimateUniversal Health Services beat the analysts' profit estimate in 7 of its last 8 quarters, the latest on Oct 27, 2026.
UHS insider selling
-$128Ksold, net, by its executives in 12 monthsUniversal Health Services' executives and directors sold a net $128K of shares in the 12 months to Nov 13, 2026; none bought.
UHS number of employees
+3%more people in a yearUniversal Health Services had 101,500 employees at the end of fiscal 2025, 3% more than a year before.
UHS CEO pay
$16.15Mfor fiscal 2025, 62% of it in stock and optionsUniversal Health Services paid its CEO $16.15M for fiscal 2025, 62% of it in stock and options.
UHS financial health Altman Z-score
2.2Altman Z-score, safe above 3Universal Health Services' Altman Z-score is 2.2 (Nov 13, 2026), between 1.8 and 3, the grey zone.
UHS quality checks Piotroski score
5 of 9checks passedUniversal Health Services passes 5 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on return on assets, long-term debt, gross margin and sales for its assets.
UHS in past recessions
pretickt analysis+2%its sales in the worst oneUniversal Health Services' sales grew through each of the last 2 US recessions (2008–09 and 2020).
UHS price vs profit P/E ratio
8.1×a year's earningsUniversal Health Services' P/E ratio is 8.1 (Nov 13, 2026), below its 3-year median of 10.2.
UHS price vs peers
pretickt analysis8.1×a year's earnings, against its peersInvestors pay 8.1 times Universal Health Services' earnings (Nov 13, 2026), less than for Insulet (24.8), Henry Schein (23.6), HCA Healthcare (16.5) or DaVita (13.7).
UHS analysts' target price target
0%to their average targetAnalysts' average price target for Universal Health Services is $193, 0% below the Nov 13, 2026 close of $194.07.
UHS growth priced in fair value
pretickt analysis-4%a year, for ten years, and still worth the priceAt $194.07 a share, Universal Health Services' free cash flow could shrink about 4% a year for ten years and still be worth the price (Nov 13, 2026).
What is Universal Health Services' P/E ratio?
Universal Health Services' P/E ratio is 8.1 (Nov 13, 2026), below its 3-year median of 10.2. Investors pay 8.1 times Universal Health Services' earnings (Nov 13, 2026), less than for Insulet (24.8), Henry Schein (23.6), HCA Healthcare (16.5) or DaVita (13.7).
Is Universal Health Services profitable?
Universal Health Services' operating margin was 11% in the 12 months to Sep 30, 2026, against 7% in fiscal 2022. Universal Health Services generated $1.12B of free cash flow in the 12 months to Sep 30, 2026, less than its reported profit.
Are insiders selling Universal Health Services stock?
Universal Health Services' executives and directors sold a net $128K of shares in the 12 months to Nov 13, 2026; none bought.
How does Universal Health Services make money?
Acute Care Hospital Services brought Universal Health Services 57% of its sales in fiscal 2025; Behavioral Health Services 43%.
How many employees does Universal Health Services have?
Universal Health Services had 101,500 employees at the end of fiscal 2025, 3% more than a year before.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.